Multiple myeloma (MM) is a malignancy of terminally differentiated B lymphocytes, characterized by accumulation of a monotypic plasma cell population in the bone marrow, monoclonal immunoglobulin in serum and/or urine and osteolytic lesions. Despite recent advances in the treatment, MM remains an incurable disease. This calls for an effort to develop novel therapeutics in order to eradicate the disease. Here we have evaluated the potential antimyeloma action of Pemetrexed, an antifolate drug that has shown promising results in other neoplastic diseases. Pemetrexed had a potent antimyeloma effect on cell lines sensitive and resistant to conventional therapeutic agents, and was also efficient on fresh cells from patients and in a murine MM model. Furthermore, Pemetrexed abrogated the protective action on MM cell death of several growth factors produced by the bone marrow microenvironment. Mechanistic studies indicated that Pemetrexed provoked this action by a combined effect that included cell cycle blockade, probably by p21 upregulation, and induction of apoptosis through caspase-dependent and -independent mechanisms. These data, together with the fact that Pemetrexed is already licensed for the therapy of other neoplastic diseases, opens the possibility for the inclusion of Pemetrexed in the therapeutic armamentarium to battle MM.
Introduction
Multiple myeloma (MM) is a malignancy of terminally differentiated B lymphocytes, characterized by accumulation of a monotypic plasma cell population in the bone marrow together with the presence of a monoclonal immunoglobulin in serum and/or urine, and osteolytic lesions. 1 MM is often preceded by an asymptomatic condition named monoclonal gammopathy of undetermined significance, that progresses to MM at a rate of 0.5-3% per year.
Despite recent advances in the treatment, MM remains an incurable disease. Because of this, efforts to develop novel compounds have resulted in the arrival to the clinic of new agents such as proteasome inhibitors (Bortezomib) or the immunomodulatory drugs (Thalidomide or Revlimid). 2 Even though these drugs have demonstrated clinical benefit in MM treatment, patients continue to relapse, and this calls for additional efforts to develop compounds and novel strategies for a more efficient control of the disease and eventually its eradication.
One of the potential targets for therapeutic intervention is DNA synthesis. The reduced folates play an essential role in the synthesis of thymidine and purine nucleotides. 3 A classical antifolate drug is Methotrexate, a folic acid homolog that impairs nucleotide production leading to disruption of DNA synthesis and cell duplication. Pemetrexed is a new multitarget antifolate metabolite that acts on the enzymes thymidylate synthase (TS), dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyl transferase (GARFT), 4 thereby depleting nucleotide pools and blocking DNA synthesis. 5, 6 Pemetrexed is transported into the cell via the reduced folate carrier and the folate binding protein. After being transported into the cell, Pemetrexed is polyglutamated by the enzyme folyl-polyglutamyl synthase. These polyglutamate derivatives are potent inhibitors of TS, and are also weaker inhibitors of GARFT. 7 Pemetrexed and its polyglutamate derivatives also inhibit DHFR, but with 1000-fold less potency than Methotrexate. 8 The mechanisms by which TS inhibitors as Pemetrexed act on cell survival and proliferation are not well understood yet, and can differ between cells. Recent studies have indicated that p21 is upregulated in a p53-independent manner in the presence of TS inhibitors in human colorectal cancer cell lines, as did thymine deprivation in TS-deficient cells. 9 In the breast cancer line MCF7, and in the colon cancer cell lines HCT116 and RKO, Fas was involved in the induction of apoptosis in response to TS inhibitors. 10 More recently, it has been shown that Pemetrexed provoked dephosphorylation of AKT in human lung cancer cell lines.
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Pemetrexed has demonstrated broad antitumor activity in cell lines derived from solid tumors. [12] [13] [14] Thus, in a human tumor cloning assay Pemetrexed showed activity against breast, pancreas, lung and colon human tumor cell lines. 13 Pemetrexed has been assessed in combination with other antitumor agents, including platinum compounds, antitubulin agents, and other antimetabolites, in vivo using EMT-6 mammary carcinoma, HCT116 colon carcinoma and H460 NSCLC xenografts in nude mice. 13, 14 Recently, Pemetrexed has been used in combination with cisplatin for patients with malignant pleural mesothelioma, and is approved for the treatment of non-small-cell lung cancer. 15, 16 Given these precendents, we decided to explore the action of Pemetrexed on MM cells. In this study, we demonstrate that Pemetrexed was active against MM cells in vitro, and in an animal MM model. The action of Pemetrexed included a blockade in MM cell cycle progression, together with increased apoptosis, the latter involving both caspase-dependent and -independent pathways. Coculture with bone marrow stromal cells (BMSCs), or interleukin-6 (IL-6) and insulin-like growth factor-1 (IGF-1), known proliferation and survival factors for MM cell lines, 17 were unable to protect against Pemetrexed-induced
Cell culture, cell proliferation and cell cycle experiments
All MM cell lines were cultured at 371C in a humidified atmosphere in the presence of 5% CO 2 95% air, and in Rosewell Park Memorial Institute (RPMI)-1640 medium with Lglutamine and supplemented with antibiotics (penicillin at 100 U/ml, streptomycin at 100 mg/ml) and 10% fetal bovine serum (FBS). BMSC and BM samples were obtained from MM patients as described previously. 18 The proliferation of MM cells was examined using 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT; Sigma) colorimetric assays, following published protocols. 18 The results are represented as the mean7s.d. of quadruplicates of a representative experiment that was repeated at least three times. Cell cycle analyses on MM1S cells were performed as described. 18 
Apoptosis assays, subcellular fractionation and Western blotting
For the apoptosis assays in MM1S cells we used the Annexin Vstaining protocol described previously. 18 Apoptosis in patient cells was performed on BM aspirates. Analyses of cell death in these patient samples were performed by multiparametric flow cytometry, as described. 18 The protocol for the subcellular fractionation experiments has been reported. 18 For Western blotting experiments, cells were collected and centrifuged at 1200 r.p.m. for 3 min. Then cells were washed with 1 ml cold phosphate-buffered saline (PBS), and total cell lysates were obtained after incubation in ice-cold lysis buffer for at least 10 min (140 mM NaCl, 10 mM ethylenediaminetetraacetic acid, 10% glycerol, 1% Nonidet P-40, 20 mM Tris (pH 7.0), 1 mM pepstatin, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mM sodium orthovanadate). Samples were then centrifuged at 10 000 r.p.m. for 10 min at 41C. The supernatants were transferred to new tubes, and equal amounts of protein, quantified by the Bradford assay, were boiled in electrophoresis sample buffer and loaded onto 8-12% gradient or 10% continuous sodium dodecyl sulfate/polyacrylamide gel electrophoresis gels. Proteins were transferred onto Immobilon P membranes (Millipore Corporation, Billerica, MA, USA), and blots subsequently incubated with the specific primary antibodies for 1 h. After washing with Tris-buffered saline Tween-20 (TBST), membranes were incubated with the corresponding HRP-conjugated secondary antibody for 30 min. After washing with TBST, immunoblots were developed by enhanced chemiluminescence. 19 
MM xenografts
CB17-severe combined immunodeficiency (SCID) mice were subcutaneously (s.c.) inoculated into the right flank with 3 Â 10 6 MM1S cells in 100 ml of RPMI-1640 medium and 100 ml of Matrigel (Becton Dickinson). When tumors became palpable, mice received Pemetrexed or vehicle alone. Treatment with Pemetrexed (n ¼ 4) was given intraperitoneally (i.p.) once a day, 5 days a week. The control group (n ¼ 5) received the vehicle alone (PBS) using the same schedule. Caliper measurements of the tumor diameters were performed every other day and the tumor volume was estimated as the volume of an ellipse, using the following formula:
2 , where 'a' and 'b' correspond to the longest and shortest diameter, respectively. Animals were euthanized when their tumors reached 2 cm.
Analyses of synergism by the CalcuSyn program
In order to determine if the combination of Pemetrexed and other anti-MM drugs was additive, antagonist or synergistic, we used the Calcusyn software program (Biosoft, Ferguson, MO, USA). This program is based upon the Chou-Talalay method according to the following equation Combination indices
where (D)1 and (D)2 are the doses of drug 1 and 2 that have the same x effect when used alone. To obtain such doses, dose-response curves were generated to determine the concentration that produced a 50% inhibition of the MTT absorbance (IC 50 ) at 48h of continuous exposure. Combinations of drugs were then generated at concentrations below and above the IC 50 values of each drug in order to determine if the combinations were additive, synergistic or antagonistic. CIs from three different experiments were generated with the CalcuSyn software for each set of combinations, in triplicate, using the results obtained from each drug alone and in combination at a constant ratio within the same experiment. CI less than 1.0 indicates synergism, CI values ¼ 1 indicate an additive effect, whereas values above 1 correspond to antagonism. The conformity of data to the median effect can be readily manifested by the linear correlation coefficient (r) of the median-effect plot: log (fa/fu) m log (D) -m log (D m ), where D is the dose, D m is the dose required for 50 % effect, fa is the fraction affected by dose, fu is the unaffected fraction, and m is a coefficient of the sigmoidicity of the doseeffect curve. In tissue culture systems, an r-value superior to 0.90 indicates a good conformity.
Statistics
Data were expressed as mean7s.d. Significance between data sets was determined by the Student's t-test. Differences were considered significant when Po0.05, and very significant when Po0.001.
Results

Action of Pemetrexed on MM cells
To investigate the effect of Pemetrexed on myeloma cells, we initially used different MM cell lines, sensitive and resistant to conventional therapies. Pemetrexed caused a significant and potent dose-dependent inhibition of MTT absorbances in MM1S, MM1R, MM144 and MGG cells with IC 50 values around 1-25 nM (Figure 1a) . The NCIH929 and RPMI-8226 cell lines showed intermediate sensivity (IC 50 : 50-100 nM and 500-1000 nM, respectively). Finally, the cell lines U266 and U266-LR7 were resistant to Pemetrexed. The effect of Pemetrexed on MM1S and MM144 cells was also time dependent (Figure 1b and c, respectively). At 24 h of treatment a small effect was observed, and at 48 h and later, the action of Pemetrexed was clearly evidenced. We also evaluated the action of Pemetrexed on plasma cells from patients. For these experiments we used a multiparametric cytometry protocol 18 that allows the analysis of the action of a drug on tumoral as well as on other normal BM constituents. Samples from four patients with MM were studied. Two of them were sensitive to Pemetrexed, and two were resistant. Data from two patients, one representative of the sensitive and the other resistant to Pemetrexed is shown in Figure 2a . In the sensitive patient (patient 1), treatment with Pemetrexed substantially increased Annexin V-FITC staining in the plasma cell population, but not in the B lymphocytes or in the granulocyte-monocyte population, indicating the specificity of the drug for the malignant plasma cells.
In vivo action of Pemetrexed
The 'in vivo' antimyeloma effect of Pemetrexed was evaluated in a xenograft-plasmocytoma model that was generated by implanting MM1S cells s.c. in CB17-SCID mice. Mice engrafted with MM1S were daily administered 100 mg/kg of Pemetrexed i.p. or vehicle alone for 5 days a week. As shown in Figure 2b , Pemetrexed was able to inhibit the tumor growth as compared to the control group with statistically significant differences (P ¼ 0.01, paired t-test). Moreover, in two of the treated mice, a reduction of the tumor volume was observed during the first weeks of treatment.
Pemetrexed provokes cell cycle arrest
We investigated whether an arrest in the cell cycle contributed to the reduced MTT absorbance in MM1S cells treated with Pemetrexed. At 12 h of treatment, Pemetrexed induced a substantial increase in the number of cells present in the S phase, together with a concomitant decrease of cells in the G2/ M phases (Figure 3a) . The proportion of cells in the G0/G1 phases did not change at this time. Extension of the incubation with Pemetrexed for 24 h resulted in accumulation of cells in the G0/G1 cell cycle phases. As Pemetrexed induced G 1 /S phase arrest in MM1S, we analyzed the levels of proteins involved in cell cycle regulation. The p21 cyclin-dependent kinase inhibitor protein increased after 12 h of treatment with Pemetrexed, and this increase peaked at 24 h (Figure 3b ). This increased level of p21 was independent of p53 expression as the levels of the latter were unaffected by Pemetrexed. Western blotting analyses of Cdk2, Cdk4, Cyclin D1 and p27 did not evidence substantial changes in their levels upon Pemetrexed treatment (Figure 3b ).
Induction of apoptosis by Pemetrexed
We also investigated whether Pemetrexed could also act on MM cells by inducing cell death. Under microscopic analysis, apoptotic bodies were observed in MM1S cells treated with Pemetrexed (Figure 4a) . Moreover, treatment of MM1S cells with 100 nM Pemetrexed for 24 or 48 h induced 40 and 80% Annexin V-FITC-positive cells, respectively (Figure 4b ). We also investigated the mitochondrial membrane potential (Dc m ) by FACS using the mitochondrial membrane potential probe 3, 3 0 -dihexyloxacarbocyanine iodide (DioC 6 (3)). Pemetrexed caused a substantial loss of Dc m after 48 h treatment (Figure 4c) . The above data were indicative of Pemetrexed inducing apoptotic cell death and suggested that mitochondria could act as a mediator in the action of this compound. As alterations in mitochondrial c m reflect increases in the mitochondrial outer membrane permeability, we analyzed whether Pemetrexed could provoke the exit of proapoptotic proteins to the cytosolic compartment. Pemetrexed caused a time-dependent translocation of cytochrome c and AIF from the mitochondrial to the cytosolic fraction (Figure 4d ).
Pemetrexed induces both caspase-dependent and -independent apoptosis
As mediators of apoptosis released by mitochondria may induce cell death through activation of caspases, 20 we next investigated whether Pemetrexed-induced cell death occurred through this mechanism. MM1S cells were treated with Pemetrexed for 6, 12, 24 and 48 h, and PARP cleavage, indicative of caspase activation, analyzed by Western blotting. PARP cleavage was clearly evidenced after 48 h of treatment (Figure 5a ). In addition, cleavage of the initiator caspases 8 and 9 was also evidenced, together with cleavage of the effector caspase 3. We also analyzed different proapoptotic factors (Bax, Bid and Bim) and antiapoptotic factors (Bcl-2, Bcl-XL and Mcl-1). At 24 h of treatment, the level of Bcl2 was unchanged with respect to control untreated cells, but was profoundly downregulated at 48 h. A similar trend was observed with Bcl-XL. Mcl-1 was clearly downregulated at 24 h of treatment with Pemetrexed. Bim was initially upregulated, but then also decreased. No major changes in Bax were observed (Figure 5b ). The potential contribution of caspases to the proapoptotic action of Pemetrexed was evaluated biologically and biochemically by the use of several caspase inhibitors. In MM1S cells the activation of apoptosis induced by Pemetrexed at 24 h was completely blocked by pretreatment with 50 mM of the pancaspase inhibitor Z-VAD-FMK (Figure 5c ). However, inhibition of apoptosis by Z-VAD-FMK was only partial after 48 h of treatment with Pemetrexed. Biochemical studies indicated that Z-VAD-FMK strongly inhibited Pemetrexed-induced PARP processing (Figure 5d) . Also, the caspase 8 inhibitor Z-IETD-FMK and the caspase-9 inhibitor Z-LEHD-FMK inhibited Pemetrexed-induced PARP cleavage.
Pemetrexed overcomes the protective effect of IL-6, IGF-1 and BMSCs on MM cells
Interaction of MM cells with BMSCs induces secretion of growth factors such as IL-6 and IGF-1, which mediate paracrine growth of MM cells, and protect against drug-induced apoptosis. 2 We therefore decided to analyze the effect of Pemetrexed on MM cells in the presence of exogenous IL-6 and IGF-1, as well as in cocultures with BMSCs. As shown in Figure 6a , IL-6 and IGF-1 provoked small increases in the MTT absorbances with respect to untreated cells. However, treatment with these factors failed to protect MM cells, against Pemetrexed-induced growth inhibition/apoptosis. Pemetrexed reduced phophorylation of Akt induced by IGF-1 and IL-6, whereas it did not affect extracellular signal-regulated kinase (ERK)1/2 dual phosphorylation induced by these growth factors (Figure 6b 
Evaluation of synergism between Pemetrexed and other anti-MM drugs
Clinical experience in the treatment of MM supports the use of combinations of compounds as more efficient than single agent treatment. To determine whether Pemetrexed could increase the action of clinically relevant antimyeloma drugs, we combined Pemetrexed with classic (Dexamethasone, Doxorubicin or Melphalan) or recently developed (Bortezomib or Revlimid) agents. For these experiments, we used suboptimal doses of these compounds, and analyzed their combined effect by MTT absorbance assays, followed by analysis of the data by the CalcuSyn program. No synergistic effect was observed when Pemetrexed was combined with Dexamethasone, Doxorubicin, Melphalan or Bortezomib (data not shown). However, the combination of Pemetrexed with Revlimid was synergistic (CI: 0.5-0.86) (Figure 7) .
Discussion
In this work we present evidence indicating that Pemetrexed is an active antimyeloma agent. Pemetrexed reduced MTT absorbance in different MM cell lines, including cells sensitive and resistant to dexamethasone. In contrast, the U266 and the melphalan-resistant derivative U266-LR7 cell lines were resistant to Pemetrexed. This differential sensitivity to Pemetrexed was also evidenced on fresh plasma cells from patients. Importantly, the activity of Pemetrexed on malignant plasma cells was significantly higher than in residual normal BM cells (B and T lymphocytes, granulocytes and monocytes), indicating that the action is specific for plasma cells. In addition, Pemetrexed reduced tumor volume in a xenografted model of MM. Finally, Pemetrexed was able to overcome the growth advantage induced by IL-6, IGF-1 and BM stromal cells. Altogether these data support the in vitro and in vivo antimyeloma activity of Pemetrexed.
Studies on the mechanism of action of Pemetrexed indicated that this compound acts through a complex and sequential number of events that affect cell cycle progression and apoptosis. In MM1S cells, Pemetrexed provoked cell cycle arrest, that was already detectable within 12 h of treatment, a time at which apoptosis was undetectable. Analyses of the proteins implicated in the control of cell cycle progression showed an increase in the amount of p21, whereas other classical cell cycle regulators, such as p27 or p53 were unchanged. The latter is interesting as p21 increases have been frequently linked to p53 upregulation. 21 However, in MM1S cells p21 was upregulated in the absence of changes in p53. The molecular mechanisms of such an increase in p21 are unknown, but may be the reflection of increased stability or synthesis triggered by p53-independent routes. Related to this finding, recent research has indicated that Tomudex, another potent inhibitor of TS activity, induced p21 upregulation in human colorectal cancer cells, also through a p53-independent route, as did thymidine deprivation in TS deficient cells. 9 It is therefore possible that p21 upregulation may play a role in Pemetrexed-induced cell cycle arrest in myeloma cells sensitive to this compound.
Temporally, after induction of cell cycle arrest, MM1S cells treated with Pemetrexed entered in apoptosis. The latter was characterized by the appearance of apoptotic bodies, augmented Annexin V-staining, and decreased mitochondrial membrane potential. The latter is often accompanied by increased permeability of the outer mitochondrial membrane with release of intermembranous material to the cytosol, including several regulators of apoptosis. Subcellular fractionation experiments demonstrated a significant release of cytochrome c from the mitochondria to the cytosol of MM1S cells treated with Pemetrexed. Released cytochrome c is known to participate, together with procaspase 9 and apoptotic protease activating factor in the assembly of active apoptosomes, that in turn trigger the proteolytic cleavage of procaspase 3, with its ensuing activation. 20 In fact, evidence indicative of caspase 3 activation was present as Western blotting experiments showed caspase 3 and PARP cleavage with generation of lower M r truncated fragments. Our data also indicated that Pemetrexed caused caspases 8 and 9 cleavage. Both caspases are know to act as upstream initiator caspases that either transduce the exogenous or endogenous caspase-dependent cell death routes, respectively. 20 The activation of caspases opened the question of whether the cell death induced by Pemetrexed required caspase activity. Biological data indicated that Pemetrexed-induced cell death was sensitive to the pancaspase inhibitor Z-VAD-FMK at early times, but the efficiency of this inhibitor decreased at extended times of treatment with Pemetrexed. This phenomenon suggests a biphasic mode of action of Pemetrexed on cell death, analogous to other potent antimyeloma agents, such as the histone Deacetylase inhibitor LBH589. 18 In this model, a first wave of apoptosis occurs through caspase-dependent cell death, as is sensitive to caspase inhibitors. This is followed by a second wave of caspase-independent cell death, characterized by resistance to caspase inhibitors. We may then wonder about the mechanism responsible for such a late phenomenon. In this respect, it should be mentioned that our data indicate that in addition to cytochrome c, mitochondria can also release AIF, and probably another apoptotic mediators, that act on cell death through caspase-independent mechanisms.
From the clinical point of view, several important considerations have to be taken into account. Obviously, one important issue raised by our data is the identification of patients that may benefit from Pemetrexed treatment. Pharmacogenomic studies on Pemetrexed activity and sensitivity would be of value in order to dissect the sensitive from the refractory patients. Another point to be considered is the already available clinical experience with Pemetrexed in mesothelioma. 3 This previous experience may facilitate the development of the use of Pemetrexed for the treatment of MM. Finally, the fact that Pemetrexed potentiated the action of Revlimid opens the possibility for the combination of these two drugs in MM patients.
In conclusion, our results show for the first time that Pemetrexed is an agent with potential use as an antimyeloma drug. It induces cell death in drug-resistant MM cells and overcomes the growth-promoting activities of IL6, IGF-1 and BMSCs. The need for novel treatments in the therapy of MM should welcome drugs such as Pemetrexed, already approved and clinically tested for other neoplastic diseases.
